Trial Profile
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Ceralasertib (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Oleclumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Vistusertib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Acronyms HUDSON
- Sponsors AstraZeneca; AstraZeneca AB
- 10 Aug 2023 Planned End Date changed from 27 Feb 2025 to 26 Sep 2024.
- 10 Aug 2023 Planned primary completion date changed from 27 Feb 2025 to 26 Sep 2024.
- 19 Apr 2023 Results (n=48 patients for gene expression analysis and n=62 patients for TCR repertoire sequencing) assessing the immunomodulatory effects (innate and adaptive immunity) of ceralasertib in combination with durvalumab of HUDSON patients with non-small cell lung cancer, presented at the 114th Annual Meeting of the American Association for Cancer Research.